



Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

September 2, 2015

[Download this Press Release](#)

Presentations to be Webcast on September 10 at 3:10 p.m. ET and September 16 at 9:20 a.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 2, 2015-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a brief corporate overview followed by a question and answer session at the following two investor conferences during the month of September:

- September 10, 2015, at 3:10 p.m. ET, Baird 2015 Healthcare Conference in New York.
- September 16, 2015 at 9:20 a.m. ET, 2015 Morgan Stanley Global Healthcare Conference in New York.

A live webcast and replay of the presentation sessions can be accessed by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at www.enanta.com. The replay webcasts will be available following the presentations and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta has developed novel protease and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta's protease inhibitors partnered with AbbVie include paritaprevir, which is contained in AbbVie's marketed DAA regimens for HCV, and ABT-493, Enanta's next generation protease inhibitor completing phase 2 development. Enanta also has a program to develop a host-targeted antiviral (HTA) inhibitor class for HCV targeted against cyclophilin, as well as another DAA program to develop nucleotide polymerase inhibitors. In addition, Enanta has a preclinical program in non-alcoholic steatohepatitis, or NASH, which is a condition that results in liver inflammation and liver damage caused by a buildup of fat in the liver.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20150902005094/en/>

Source: Enanta Pharmaceuticals, Inc.

Investor Contact

Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com